Tags

Type your tag names separated by a space and hit enter

Seborrheic dermatitis.
Dermatol Clin. 2003 Jul; 21(3):401-12.DC

Abstract

Seborrheic dermatitis is present in 1% to 3% of immunocompetent adults, and is more prevalent in men than in women. Seborrheic dermatitis may be seen in conjunction with other skin diseases, such as rosacea, blepharitis or ocular rosacea, and acne vulgaris. Malassezia yeasts have been associated with seborrheic dermatitis. Abnormal or inflammatory immune system reactions to these yeasts may be related to development of seborrheic dermatitis. Treatment modalities for seborrheic dermatitis include keratolytic agents, corticosteroids, and more recently, antifungal agents. Antifungal agents do not carry a risk of skin atrophy or telangiectasia with prolonged use, and it is more prudent to consider antifungals than corticosteroid preparations. The wide range of antifungal formulations available (creams, shampoos, or oral) provides safe, effective, and flexible treatment options for seborrheic dermatitis.

Authors+Show Affiliations

Gupta AK
Division of Dermatology, Department of Medicine, Sunnybrook and Women's College Health Science Center (Sunnybrook Site), University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada. agupta@execulink.com
Bluhm R
No affiliation info available
Cooper EA
No affiliation info available
Summerbell RC
No affiliation info available
Batra R
No affiliation info available

MeSH

Administration, CutaneousAdministration, OralAntifungal AgentsDermatitis, SeborrheicHumansMalassezia

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

12956195

Citation

Gupta, Aditya K., et al. "Seborrheic Dermatitis." Dermatologic Clinics, vol. 21, no. 3, 2003, pp. 401-12.
Gupta AK, Bluhm R, Cooper EA, et al. Seborrheic dermatitis. Dermatol Clin. 2003;21(3):401-12.
Gupta, A. K., Bluhm, R., Cooper, E. A., Summerbell, R. C., & Batra, R. (2003). Seborrheic dermatitis. Dermatologic Clinics, 21(3), 401-12.
Gupta AK, et al. Seborrheic Dermatitis. Dermatol Clin. 2003;21(3):401-12. PubMed PMID: 12956195.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Seborrheic dermatitis. AU - Gupta,Aditya K, AU - Bluhm,Robyn, AU - Cooper,Elizabeth A, AU - Summerbell,Richard C, AU - Batra,Roma, PY - 2003/9/6/pubmed PY - 2003/10/11/medline PY - 2003/9/6/entrez SP - 401 EP - 12 JF - Dermatologic clinics JO - Dermatol Clin VL - 21 IS - 3 N2 - Seborrheic dermatitis is present in 1% to 3% of immunocompetent adults, and is more prevalent in men than in women. Seborrheic dermatitis may be seen in conjunction with other skin diseases, such as rosacea, blepharitis or ocular rosacea, and acne vulgaris. Malassezia yeasts have been associated with seborrheic dermatitis. Abnormal or inflammatory immune system reactions to these yeasts may be related to development of seborrheic dermatitis. Treatment modalities for seborrheic dermatitis include keratolytic agents, corticosteroids, and more recently, antifungal agents. Antifungal agents do not carry a risk of skin atrophy or telangiectasia with prolonged use, and it is more prudent to consider antifungals than corticosteroid preparations. The wide range of antifungal formulations available (creams, shampoos, or oral) provides safe, effective, and flexible treatment options for seborrheic dermatitis. SN - 0733-8635 UR - https://www.unboundmedicine.com/medline/citation/12956195/Seborrheic_dermatitis_ DB - PRIME DP - Unbound Medicine ER -